CClinicalTrials.gg
Status unknownNCT01564498Updated Oct 26, 2016

Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors

A Phase 1 interventional study of vegetable in Hypertension, Hypercholesterolemia and Type II Diabetes, sponsored by University of Guelph. Status unknown at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-26.

Sponsored by University of Guelph · Phase 1, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The hypothesis is that richly coloured purple vegetables, rich in polyphenolic compounds including anthocyanins will have higher antioxidant and other biological activities, than more lightly coloured versions of these foods. Diets of human subjects will be modified to allow consumption of 200-300 g of raw carrots or cooked potatoes. Participants will be randomized to consume either orange or purple carrots, or white or purple potatoes. They will consume these diets for 12 weeks and bioavailability of polyphenolics will be examined as well as anthropometry and blood biochemistry for changes in risk factors associated with cardiovascular disease.

02

Conditions studied

  • Hypertension
  • Hypercholesterolemia
  • Type II Diabetes
  • Obesity
  • Inflammation

Keywords

  • anthocyanins
  • antioxidant
  • polyphenols
  • bioavailability
  • cholesterol
  • insulin sensitivity
  • glucose tolerance
  • atherosclerosis
  • metabolic syndrome
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of Guelph is the lead sponsor of 69 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • adult men and women 18-65 years of age
  • must have a least one of the following risk factors associated with increased risk of type II diabetes and/or cardiovascular disease:

    • borderline high or hypertension or undergoing treatment for such
    • abnormal fasting blood glucose or undergoing treatment for such
    • overweight or obese
    • borderline high or high LDL-cholesterol or undergoing treatment for such
    • borderline low or low HDL-cholesterol
    • borderline high or high triglycerides or undergoing treatment for such

Exclusion criteria

Exclusion Criteria:

  • smokers, pregnant or nursing women
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    White potato

    Participants will consume 300-500 g of cooked white potatoes per day

    Other: vegetable

  • Experimental
    Purple Potato

    Participants will consume 300-500 g of cooked purple potato per day

    Other: vegetable

  • Placebo comparator
    Orange carrots

    Participants will consume 200-300 g typical varieties of orange carrots during the intervention

    Other: vegetable

  • Experimental
    Purple Carrots

    Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm

    Other: vegetable

Interventions

  • Othervegetable

    200-300 g raw carrots or 300-500 g cooked potatoes

06

What researchers measure

Primary outcomes

  1. Blood cholesterol

    blood will be collected at baseline before the experimental foods are introduced and again 6 weeks into the intervention period and during the last week of the intervention (week 12)

    Time frame: 12 weeks

Secondary outcomes

  1. blood pressure

    Participants will have their body weight and blood pressure taken at weekly counselling sessions

    Time frame: 12 weeks

  2. body composition

    body composition will be measured in well hydrated subjects using bioelectric impedence analysis

    Time frame: 12 weeks

  3. insulin resistance

    insulin resistance will be measured by way of an oral glucose tolerance test and collection of venous blood samples for the subsequent 3 hours on two occasions, baseline and during the last week of the intervention diet.

    Time frame: 12 weeks

  4. blood and urinary polyphenol metabolites

    venous blood and urine will be collected to determine the metabolic profiles of polyphenolics in individual participants. Based on intake data, the bioavailability of the polyphenols in the foods will be estimated.

    Time frame: 12 weeks

  5. circulating biomarkers of cardiovascular disease and type II diabetes risk

    Blood will be collected for measurement of multiple cytokines, growth factors and other blood biomarkers associated with these diseases.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Human Nutraceutical Research Unit
    Guelph, Ontario N1G2W1, Canada
    • Amanda J Wright, PhD · Contact · ajwright@uoguelph.ca · 5198244120
    • Amy Tucker, PhD · Contact · 5198244120
    • Kelly A Meckling, PhD · Principal investigator
    • Saqib Mannan, BSc · Sub investigator
    • Ricky Janssen, BSc · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01564498
Lead sponsor
University of Guelph
Collaborators
Ontario Ministry of Agriculture, Food and Rural Affairs
Responsible party
Kelly Anne Meckling, PhD (Professor, University of Guelph) — Principal investigator
First posted
Mar 27, 2012
Start date
Apr 2012
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Oct 26, 2016

Study contacts

Kelly A Meckling, PhD
Contact
kmecklin@uoguelph.ca
5198244120 ext. 53742
Saqib Mannan, BSc
Contact
smannan@uoguelph.ca
5198244120 ext. 53728

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion